Get the Stockscreener App
14.81
6.42%
-1.07
After Hours:
14.66
-0.15
-1.01%
Rallybio Corp stock is traded at $14.81, with a volume of 34,218.
It is down -6.42% in the last 24 hours and up +72.19% over the past month.
Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.
See More
Previous Close:
$15.88
Open:
$15.74
24h Volume:
34,218
Relative Volume:
0.11
Market Cap:
$78.47M
Revenue:
$858.00K
Net Income/Loss:
$-8.98M
P/E Ratio:
-71.93
EPS:
-0.2059
Net Cash Flow:
$-29.81M
1W Performance:
+4.72%
1M Performance:
+72.19%
6M Performance:
+188.88%
1Y Performance:
+464.08%
1-Day Range:
$14.67
$15.86
1-Week Range:
$14.05
$16.00
52-Week Range:
$2.16
$16.00
Rallybio Corp Stock (RLYB) Company Profile
Name
Rallybio Corp
Sector
Industry
Phone
203- 859-3820
Address
234 CHURCH STREET, NEW HAVEN
Compare RLYB vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RLYB
Rallybio Corp
|
14.81 | 84.13M | 858.00K | -8.98M | -29.81M | -0.2059 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Rallybio Corp Stock (RLYB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-09-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-15-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-07-24 | Downgrade | Jefferies | Buy → Hold |
| Apr-17-23 | Initiated | H.C. Wainwright | Buy |
| Apr-10-23 | Initiated | Wedbush | Outperform |
| Dec-09-22 | Initiated | JP Morgan | Overweight |
| Feb-22-22 | Initiated | JMP Securities | Mkt Outperform |
| Aug-23-21 | Initiated | Cowen | Outperform |
| Aug-23-21 | Initiated | Evercore ISI | Outperform |
| Aug-23-21 | Initiated | Jefferies | Buy |
View All
Rallybio Corp Stock (RLYB) Latest News
Rallybio Corporation Q1 2026 Earnings: Wider Loss Reflects R&D Investment, Stock GainsBuyback Announcement Report - Newser
RLYB Stock Chart | RALLYBIO CORP (NASDAQ:RLYB) - ChartMill
Adar1 Capital Management, Daniel Schneeberger buy $226k Rallybio stock By Investing.com - Investing.com Nigeria
Can Rallybio Corporation (RLYB) Sustain Its +0.65% Momentum This Week? 2026-05-21Open Signal Network - Newser
Adar1 Capital Management, Daniel Schneeberger buy $226k Rallybio stock - Investing.com India
ADAR1-managed funds boost Rallybio (RLYB) stake with open-market share buys - Stock Titan
Rallybio Corporation (RLYB) Q1 2026 Earnings Miss by Significant: Key TakeawaysEPS Growth Rate - Newser
Rallybio Stock (RLYB) Opinions on Merger Termination Fee and Insider Buys - Quiver Quantitative
Insider Stock Purchases: May 16, 2026 - Quiver Quantitative
Adar1 Capital Management buys $1.11m of Rallybio (RLYB) stock By Investing.com - Investing.com South Africa
Why Rallybio Corporation (RLYB) Just Surged +0.63% — Key Levels Ahead 2026-05-15Open Stock Signal Network - newser.com
Adar1 Capital Management buys $1.11m of Rallybio (RLYB) stock - Investing.com
ADAR1 funds boost Rallybio (RLYB) stake with May open-market buys - Stock Titan
Viking Global Group (RLYB) discloses 528,954 shares, 9.99% stake - Stock Titan
Nantahala and principals report 300,635 RallyBio shares (RLYB) - Stock Titan
Cormorant (RLYB) reports 400,000 shares (7.56%) held by fund - Stock Titan
Balyasny group discloses 376,573 Rallybio shares (NASDAQ: RLYB) - Stock Titan
What's Driving Rallybio's Recent Surge and Investor Interest - Kavout
Adar1 capital, manager Daniel Schneeberger buy $711,054 Rallybio stock. By Investing.com - Investing.com Nigeria
Adar1 capital, manager Daniel Schneeberger buy $711,054 Rallybio stock. - Investing.com
Rallybio (RLYB) insider funds add 50,800 shares in open-market buys - Stock Titan
Rallybio Corporation Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Rallybio (NASDAQ: RLYB) trims Q1 loss, set to receive $50M termination fee - Stock Titan
Adar1 Capital, Daniel Schneeberger buy $2.18m Rallybio stock By Investing.com - Investing.com Nigeria
Adar1 Capital, Daniel Schneeberger buy $2.18m Rallybio stock - Investing.com
ADAR1-managed funds boost Rallybio Corp (RLYB) stake with open-market buys - Stock Titan
Rallybio (RLYB) gets new 10% insider filing from ADAR1 group - Stock Titan
5AM Ventures group reports 0% Rallybio (RLYB) ownership after May 4 share sales - Stock Titan
Rallybio(RLYB) Stock Options Chain | Quotes & News - Moomoo
[RW] Rallybio Corp SEC Filing - Stock Titan
Rallybio stock surges after receiving $50M termination fee By Investing.com - Investing.com South Africa
Rallybio stock surges after receiving $50M termination fee - Investing.com
Rallybio merger scrapped; New Haven biotech to receive $50M breakup fee - Hartford Business Journal
Rallybio Corporation Files Form 8-K with SEC Detailing Waiver Agreement and Entity Information - Minichart
RLYB Stock Under Pressure As Merger Scrutiny Mounts - timothysykes.com
Rallybio Receives Termination Fee After Candid Deal Collapse - TipRanks
Rallybio, Candid and UCB Sign Waiver; $50 Million Fee Follows Merger Termination - TradingView
Rallybio CorpCandid terminates merger agreement with Rallybio on May 3, 2026SEC filing - marketscreener.com
Rallybio (RLYB) to receive $50,000,000 after Candid chooses UCB deal - Stock Titan
Candid Therapeutics, Inc. cancelled the acquisition of Rallybio Corporation in a reverse merger transaction. - marketscreener.com
Laurion Capital (RLYB) discloses 302,756 shares, 5.72% stake - Stock Titan
RLYB - Finviz
RLYB Technical Analysis | Trend, Signals & Chart Patterns | RALLYBIO CORP (NASDAQ:RLYB) - ChartMill
[S-4/A] Rallybio Corp Amended Business Combination Registration | RLYB SEC FilingForm S-4/A - Stock Titan
Rallybio Corporation (RLYB) Sector Rotation | Rallybio Corporation notches 13.9% EPS beat on narrower lossCommunity Buy Signals - Xã Vĩnh Công
Rallybio Corp Stock (RLYB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Rallybio Corp Stock (RLYB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| ADAR1 Capital Management, LLC | 10% Owner |
May 18 '26 |
Buy |
13.98 |
6,009 |
83,981 |
916,152 |
| ADAR1 Capital Management, LLC | 10% Owner |
May 13 '26 |
Buy |
13.99 |
79,259 |
1,108,807 |
909,843 |
| ADAR1 Capital Management, LLC | 10% Owner |
May 15 '26 |
Buy |
13.90 |
300 |
4,170 |
910,143 |
| ADAR1 Capital Management, LLC | 10% Owner |
May 11 '26 |
Buy |
14.00 |
50,000 |
699,992 |
829,784 |
| ADAR1 Capital Management, LLC | 10% Owner |
May 12 '26 |
Buy |
13.83 |
800 |
11,063 |
830,584 |
| ADAR1 Capital Management, LLC | 10% Owner |
May 04 '26 |
Buy |
13.97 |
120,804 |
1,687,409 |
744,683 |
| ADAR1 Capital Management, LLC | 10% Owner |
May 05 '26 |
Buy |
14.00 |
35,101 |
491,260 |
779,784 |
| Lieber Jonathan I | Chief Financial Officer |
Feb 23 '26 |
Sale |
5.06 |
789 |
3,992 |
4,115 |
1.49%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):